SCHEMBL3514698

SCHEMBL3514698

COc1ccc(-c2ccc3ncc4[nH]c(=O)n(-c5cn(C)nc5C)c4c3c2)cc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 9/20 0.45
BRD2 P25440 7/20 0.45
BRD3 Q15059 7/20 0.45
CYP3A4 P08684 5/20 0.45
CYP2C9 P11712 5/20 0.45
MAPT P10636 1/20 0.41
MAP3K11 Q16584 2/20 0.39
CACNA1A O00555 1/20 0.39
CHRNA1 P02708 1/20 0.39
CYP2D6 P10635 1/20 0.39
CCL2 P13500 1/20 0.39
KCNA5 P22460 1/20 0.39
TACR1 P25103 1/20 0.39
MAOB P27338 1/20 0.39
CYP2C19 P33261 1/20 0.39
AVPR1A P37288 1/20 0.39
PDE4B Q07343 1/20 0.39
KCNH2 Q12809 1/20 0.39
SCN5A Q14524 1/20 0.39
BRDT Q58F21 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2068303 0.88 MTOR (0.46) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL2066364 0.86 PIK3CA (0.49) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL3516216 0.83 ATM (0.42) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL3516922 0.83 ATM (0.49) ATMATRPIK3CAMTORPIK3CD
SCHEMBL3517695 0.82 MTOR (0.52) MAPTATMATRPIK3CAMTOR
SCHEMBL3514843 0.81 CASP3 (0.40) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL3515979 0.79 MAPT (0.43) MAPTATMATRPIK3CAMTOR
SCHEMBL3516634 0.77 MTOR (0.49) ATMATRPIK3CAMTORPIK3CD
SCHEMBL3515127 0.77 MTOR (0.49) ATMATRPIK3CAMTORPIK3CD
SCHEMBL3519127 0.76 MTOR (0.47) ATMATRPIK3CAMTORPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US claimed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US claimed
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 BRD4 277/4885BRD2 757/4885BRD3 334/4885
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 BRD4 277/4885BRD2 757/4885BRD3 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.